1030 related articles for article (PubMed ID: 15456328)
1. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
Haddad PM; Wieck A
Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
[TBL] [Abstract][Full Text] [Related]
2. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
3. [Hyperprolactinemia in mentally ill patients].
Carvalho MM; Góis C
Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
[TBL] [Abstract][Full Text] [Related]
4. Prolactin awareness: an essential consideration for physical health in schizophrenia.
Montejo AL
Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.
Wieck A; Haddad PM
Br J Psychiatry; 2003 Mar; 182():199-204. PubMed ID: 12611781
[TBL] [Abstract][Full Text] [Related]
7. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
9. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
Haefliger T; Bonsack C
Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
Haddad PM; Hellewell JS; Wieck A
J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Hummer M; Huber J
Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
[TBL] [Abstract][Full Text] [Related]
12. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
Holt RI
J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
[TBL] [Abstract][Full Text] [Related]
13. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.
Smith S; Wheeler MJ; Murray R; O'Keane V
J Clin Psychopharmacol; 2002 Apr; 22(2):109-14. PubMed ID: 11910254
[TBL] [Abstract][Full Text] [Related]
14. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic-induced hyperprolactinaemia.
Inder WJ; Castle D
Aust N Z J Psychiatry; 2011 Oct; 45(10):830-7. PubMed ID: 21714721
[TBL] [Abstract][Full Text] [Related]
17. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
Peuskens J; Pani L; Detraux J; De Hert M
CNS Drugs; 2014 May; 28(5):421-53. PubMed ID: 24677189
[TBL] [Abstract][Full Text] [Related]
18. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
Cookson J; Hodgson R; Wildgust HJ
J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
Meaney AM; Smith S; Howes OD; O'Brien M; Murray RM; O'Keane V
Br J Psychiatry; 2004 Jun; 184():503-8. PubMed ID: 15172944
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-induced hyperprolactinemia.
Bostwick JR; Guthrie SK; Ellingrod VL
Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]